Cargando…

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function

The selective vasopressin V2–receptor antagonist tolvaptan is eliminated almost exclusively by non-renal mechanisms. As renal impairment can influence the pharmacokinetics of drugs even when eliminated by non-renal mechanisms, we evaluated the effect of renal insufficiency on the pharmacokinetics/ph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shoaf, Susan E, Bricmont, Patricia, Mallikaarjun, Suresh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973039/ https://www.ncbi.nlm.nih.gov/pubmed/24048380 http://dx.doi.org/10.1038/ki.2013.350

Ejemplares similares

Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults
por: Shoaf, Susan E., et al.
Publicado: (2017)

Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters
por: Shoaf, Susan E., et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial
por: Shoaf, Susan E., et al.
Publicado: (2017)

Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer
por: Souwer, E. T. D., et al.
Publicado: (2023)

Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
por: Lanke, Shankar, et al.
Publicado: (2019)

Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers
por: Härtter, Sebastian, et al.
Publicado: (2012)

The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus
por: Dudkowski, Caroline, et al.
Publicado: (2016)

Review of Tolvaptan’s Pharmacokinetic and Pharmacodynamic Properties and Drug Interactions
por: Bhatt, Purav R., et al.
Publicado: (2014)

Evaluation of pharmacokinetic and pharmacodynamic parameters of meropenem in critically ill patients with acute kidney disease
por: Hassanpour, Rezvan, et al.
Publicado: (2021)

Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function
por: Hoover, Randall K., et al.
Publicado: (2017)

Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
por: Lee, Sun Ku, et al.
Publicado: (2017)

Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects
por: Boettcher, Michael, et al.
Publicado: (2020)

The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations
por: Perrone, Ronald D., et al.
Publicado: (2020)

Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease
por: Kanter, Julie, et al.
Publicado: (2022)

Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors
por: Creelan, Ben C, et al.
Publicado: (2017)

A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD
por: Perrone, Ronald D., et al.
Publicado: (2020)

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
por: Weller, Stephen, et al.
Publicado: (2013)

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
por: Choi, Chungam, et al.
Publicado: (2018)

A Phase 1 Study To Assess the Pharmacokinetics of Intravenous Plazomicin in Adult Subjects with Varying Degrees of Renal Function
por: Komirenko, Allison S., et al.
Publicado: (2018)

Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases
por: Albach, Fredrik N., et al.
Publicado: (2017)

Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics
por: Townsend, Robert W., et al.
Publicado: (2017)

Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors
por: Savelieva, Marina, et al.
Publicado: (2015)

First‐in‐human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS‐962212, a direct, reversible, small molecule factor XIa inhibitor in non‐Japanese and Japanese healthy subjects
por: Perera, Vidya, et al.
Publicado: (2018)

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4
por: Devuyst, Olivier, et al.
Publicado: (2017)

An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia
por: Piena, Marjanne A., et al.
Publicado: (2021)

The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor
por: Kielbasa, William, et al.
Publicado: (2013)

The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease
por: Rabinovich‐Guilatt, L., et al.
Publicado: (2015)

Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open‐Label, Randomized Study
por: Adkison, Kimberly, et al.
Publicado: (2017)

Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil
por: Trivedi, Ashit, et al.
Publicado: (2021)

Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects
por: Moore, Kenneth Todd, et al.
Publicado: (2015)

Pharmacokinetic profile of defibrotide in patients with renal impairment
por: Tocchetti, Paola, et al.
Publicado: (2016)

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab‐Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results
por: O'Reilly, Eileen M., et al.
Publicado: (2017)

Pharmacokinetics of Oral Tebipenem Pivoxil Hydrobromide in Subjects with Various Degrees of Renal Impairment
por: Patel, Gina, et al.
Publicado: (2022)

Clinical Pharmacokinetics of Sulfobutylether‐β‐Cyclodextrin in Patients With Varying Degrees of Renal Impairment
por: Hoover, Randall K., et al.
Publicado: (2018)

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Normal or Varying Degrees of Impaired Renal Function
por: Mayer, Michael, et al.
Publicado: (2014)

A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects
por: Liu, Chao, et al.
Publicado: (2019)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

Safety and pharmacokinetics of SPR206 in subjects with varying degrees of renal impairment
por: Bruss, Jon B., et al.
Publicado: (2023)

Pharmacokinetics and Safety of a Single Oral Dose of Mirogabalin in Japanese Subjects With Varying Degrees of Renal Impairment
por: Kato, Manabu, et al.
Publicado: (2017)

Pharmacokinetics of transdermal buprenorphine patch in the elderly
por: Al-Tawil, Nabil, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2tohjqgdk4bqa8219qsb8iv0fe